AustralianSuper Pty Ltd Boosts Stake in Alnylam Pharmaceuticals, Inc. $ALNY

AustralianSuper Pty Ltd lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 36.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,742 shares of the biopharmaceutical company’s stock after purchasing an additional 1,524 shares during the period. AustralianSuper Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $2,618,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $662,837,000. Holocene Advisors LP purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $194,616,000. Orbis Allan Gray Ltd raised its position in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the last quarter. Massachusetts Financial Services Co. MA purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $162,577,000. Finally, Vanguard Group Inc. boosted its holdings in Alnylam Pharmaceuticals by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock worth $4,336,064,000 after buying an additional 240,534 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the sale, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 56,955 shares of company stock worth $24,072,733. 1.50% of the stock is owned by company insiders.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Barclays initiated coverage with an overweight (positive) recommendation — new institutional attention and an overweight start can attract buyers and support the share price. Barclays Initiates Coverage on Alnylam
• Positive Sentiment: Bank of America lowered its price target from $529 to $462 but maintained a Buy rating (implies ~36.7% upside vs. current price), which is supportive versus a full downgrade. BofA PT cut to $462
• Positive Sentiment: HC Wainwright cut its target from $570 to $510 but kept a Buy rating (implies ~50.9% upside), another vote of confidence from a sell-side firm. HC Wainwright PT cut to $510
• Positive Sentiment: Alnylam outlined a new five‑year strategy, “Alnylam 2030,” and is projecting ~ $5.3B revenue for 2026 — strategic growth targets and a multi‑year plan can support investor confidence in long‑term upside. Alnylam projects 2026 revenue ~$5.3B
• Neutral Sentiment: Alnylam will webcast a conference call to discuss Q4 and full‑year 2025 results — standard corporate event that may move the stock depending on actual results and guidance. Webcast of Q4/FY2025 results
• Neutral Sentiment: Reported short‑interest data shows effectively zero reported short position (data appears inconsistent/placeholder); this item is unlikely to explain intraday moves. (Internal short‑interest report)
• Negative Sentiment: Morgan Stanley lowered its price target from $495 to $408 and moved to an Equal Weight rating — a visible downgrade in sentiment from a major bank which likely pressured the stock. Morgan Stanley PT cut to $408
• Negative Sentiment: Technical context: the stock is trading below both its 50‑day (~$401.57) and 200‑day (~$423.47) moving averages, which can amplify downside as trend‑following and momentum flows react.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ALNY shares. Jefferies Financial Group reduced their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a report on Thursday, October 30th. JPMorgan Chase & Co. reduced their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Morgan Stanley reduced their target price on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Piper Sandler restated an “overweight” rating and set a $489.00 price target (up from $449.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $477.13.

Alnylam Pharmaceuticals Trading Down 2.5%

NASDAQ ALNY opened at $338.06 on Friday. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The stock has a market capitalization of $44.66 billion, a P/E ratio of 1,408.58 and a beta of 0.32. The firm’s 50-day moving average is $399.61 and its two-hundred day moving average is $423.63. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.